We’re still figuring out the side effects of GLP-1 weight-loss drugs

Recent research suggests that GLP-1 weight-loss drugs, such as those produced by Eli Lilly and Novo Nordisk, may offer longevity benefits by reducing biological age in diabetic and overweight patients. While these medications are increasingly popular—with 11% of Americans currently using them for weight loss—their rapid adoption has outpaced our full understanding of potential side effects. Beyond common gastrointestinal issues like nausea and constipation, concerns have been raised regarding links to pancreatitis, gallstone disease, and potential vision complications. Studies have also explored associations with hair loss and nail disorders. Furthermore, as prescriptions for children rise, the World Health Organization has issued guidelines advising against pharmacological obesity treatments for children under 10 due to insufficient data on long-term impacts on growth and development. As usage continues to climb, ongoing research remains critical to identifying the full spectrum of risks associated with these powerful medications.